04/08/2026
At the British Association of Dermatologists (BAD) Annual Meeting, several presentations highlighted new real-world insights from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), exploring important questions around the treatment of psoriasis. Here Dr Zenas Yiu from The University of Manchester Faculty of Biology, Medicine and Health and Northern Care Alliance NHS Foundation Trust looks at some of the discussions, the wider value of real-world evidence, and the need to improve research inclusion across routinely collected and observational datasets.
📢 What can real-world data tell us about psoriasis treatment?
At BAD 2026, Dr Zenas Yiu discusses new insights from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), including infection risk across systemic therapies, the potential for earlier biologic use and emerging risk factors for erythrodermic psoriasis.
The interview also explores the growing role of real-world evidence in improving psoriasis care and informing future research.
Read more 👉 https://touchderma.com/2026/07/13/badbir-2026-psoriasis-treatment-and-risk-factors/